All-trans Retinoic Acid Inhibits Type 1 Diabetes by T Regulatory (Treg)-Dependent Suppression of Interferon-γ–Producing T-cells Without Affecting Th17 Cells by Van, Yang-Hau et al.
All-trans Retinoic Acid Inhibits Type 1 Diabetes by T
Regulatory (Treg)-Dependent Suppression of
Interferon-–Producing T-cells Without Affecting
Th17 Cells
Yang-Hau Van,
1,2 Wen-Hui Lee,
1 Serina Ortiz,
1 Mi-Heon Lee,
1 Han-Jun Qin,
1 and Chih-Pin Liu
1
OBJECTIVE—All-trans retinoic acid (ATRA), a potent deriva-
tive of vitamin A, can regulate immune responses. However, its
role in inducing immune tolerance associated with the preven-
tion of islet inﬂammation and inhibition of type 1 diabetes
remains unclear.
RESEARCH DESIGN AND METHODS—We investigated the
mechanisms underlying the potential immunoregulatory effect of
ATRA on type 1 diabetes using an adoptive transfer animal model
of the disease.
RESULTS—Our data demonstrated that ATRA treatment inhib-
ited diabetes in NOD mice with established insulitis. In addition,
it suppressed interferon (IFN)-–producing CD4
 and CD8
 T
effector (Teff) cells and expanded T regulatory (Treg) cells in
recipient mice transferred with diabetic NOD splenocytes, with-
out affecting either interleukin (IL)-17 – or IL-4–producing cells.
Consistent with these results, ATRA reduced T-bet and STAT4
expression in T-cells and decreased islet-inﬁltrating CD8
 T-
cells, suppressing their activation and IFN-/granzyme B expres-
sion. Depletion of CD4
CD25
 Treg cells impaired the inhibitory
effect of ATRA on islet-inﬁltrating T-cells and blocked its protec-
tive effect on diabetes. Therefore, ATRA treatment induced Treg
cell–dependent immune tolerance by suppressing both CD4

and CD8
 Teff cells while promoting Treg cell expansion.
CONCLUSIONS—These results demonstrate that ATRA treat-
ment promoted in vivo expansion of Treg cells and induced Treg
cell–dependent immune tolerance by suppressing IFN-–produc-
ing T-cells, without affecting Th17 cells. Our study also provides
novel insights into how ATRA induces immune tolerance in vivo
via its effects on Teff and Treg cells. Diabetes 58:146–155,
2009
D
isorders associated with the inability to main-
tain the balance between different subsets of
T-cells may result in T-cell–mediated destruc-
tive autoimmunity (1). For example, activation
and expansion of CD4
 or CD8
 T effector (Teff) cells that
produce proinﬂammatory cytokines, such as interferon
(IFN)-, and/or attenuation of the number or function of
CD4
 T regulatory (Treg) cells, can lead to target tissue
destruction and induce autoimmune diseases (1–5). Re-
cent studies demonstrated that, in addition to IFN-–
producing Teff cells, interleukin (IL)-17–producing CD4

Th17 cells represent a new population of Teff cells that
induce potent inﬂammatory responses leading to autoim-
mune diseases (6). Additional studies showed that the
differentiation of CD4
 T-cells directed either toward
Foxp3
 Treg cells or Th17 cells was tightly regulated by
cytokine and transcriptional control (6,7). These results
suggest that the establishment of effective in vivo immune
tolerance to treat autoimmune diseases such as type 1
diabetes requires simultaneous targeting of more than one
T-cell population subset. Therefore, clinically relevant
agents or methods that induce immune tolerance by
affecting different T-cell subsets may represent an effective
approach to treating human autoimmune diseases. Studies
to understand how such an approach might affect various
T-cell subsets will help to elucidate the mechanisms
underlying the induction of immune tolerance and inhibi-
tion of inﬂammation in autoimmune diseases.
All-trans retinoic acid (ATRA) is a potent derivative of
vitamin A that has been clinically used for effective
treatment of acute promyelocytic leukemia and skin dis-
ease (8,9). Both vitamin A and ATRA have important
immune modulatory functions. For example, vitamin A
deﬁciency can lead to exacerbation of experimental auto-
immune colitis (10), as well as an excess of Th1 and a
reduction of Th2 cell responses in animals with parasite
infection (11). Supplementation of vitamin A to animals
results in a decrease in serum pro-inﬂammatory cytokines,
including tumor necrosis factor- and IFN-, and an
increase in the immunosuppressive cytokine IL-10 (12,13).
However, the mechanisms underlying the role of vitamin A
or ATRA treatment in tolerance induction regulating auto-
immune disease development have not been fully eluci-
dated (13–17). Additionally, it is not clear whether ATRA
treatment can inhibit type 1 diabetes. Because ATRA is a
potent derivative of vitamin A and has been used in patient
treatment, it is important to evaluate its role in regulating
type 1 diabetes and to determine the mechanisms by
which ATRA may inhibit the disease, so as to further
elucidate the potential beneﬁts of its clinical use in the
treatment of type 1 diabetes.
Recent in vitro studies showed that ATRA may lead to
expansion of Foxp3
 Treg cells and downregulation of
Th1 and Th17 cell differentiation (18–20). ATRA-induced
Treg cells showed gut-homing tendency and were more
potent in inhibiting experimental autoimmune colitis than
Treg cells induced by transforming growth factor (TGF)-
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146 DIABETES, VOL. 58, JANUARY 2009alone (20–22). In addition, dendritic cells isolated from gut
and gut-associated lymph nodes, which are able to pro-
duce endogenous ATRA, induced greater Foxp3 expres-
sion when cultured in vitro with TGF- than did dendritic
cells isolated from other tissues (23). These in vitro results
suggested that ATRA had distinctive effects on Teff cells
compared with Treg cell subsets.
While these data demonstrated that ATRA had varied
effects on different T-cell subsets, they did not clarify
whether ATRA inhibited type 1 diabetes, nor did they eluci-
date the mechanisms underlying its in vivo induction of
tolerance, which ultimately inhibits autoimmunity and leads
to disease. This study addresses these important questions.
RESEARCH DESIGN AND METHODS
Mice. NOD and NOD/scid mice, purchased from the Jackson Laboratory (Bar
Harbor, ME), were bred and housed in a speciﬁc pathogen-free environment
in the animal facility at the Beckman Research Institute (City of Hope, Duarte,
CA). Around 70–80% of female NOD mice developed diabetes by the age of 6
months. NOD/scid mice at 6–8 weeks old were used as recipients for
experiments.
Experimental model and ATRA treatment. Splenocytes used for adoptive
transfer studies were isolated from newly diabetic NOD mice (within 5 days of
positive urine glucose tests of 2% for at least 2 consecutive days). Nonde-
pleted splenocytes (1  10
7/mouse) were intravenously transferred into
NOD/scid mice. From day 1 of cell transfer, mice were treated intraperitone-
ally with either ATRA (0.5 mg/mouse; Sigma, St. Louis, MO) or vehicle (corn
oil) every other day (13). In some transfer studies, CD4
CD25
 cells were
depleted from splenocytes using magnetic beads (Miltenyi Biotec, Auburn,
CA). NOD mice (10 weeks old) were used for testing the effect of ATRA on
spontaneous diabetes development.
Isolation of tissue cells and intracellular staining. For isolation of
islet-inﬁltrating lymphocytes, pancreata were inﬂated with RPMI medium
containing collagenase P (1 mg/ml) and islets were isolated using a histopaque
gradient. Lymph nodes were digested with collagenase D (2 mg/ml) for
isolation of lymph node cells. To isolate splenocytes, spleens were mechani-
cally disrupted.
Cells were stimulated (3 h) with phorbol myristate acetate (5 ng/ml) and
ionomycin (500 ng/ml) in the presence of monensin (3 mol/l), stained with
antibodies, ﬁxed with paraformaldehyde (4%), permeabilized in saponin (4%)
buffer (24), and then used for intracellular staining.
In vivo IFN- secretion assay. Mice were intravenously injected with
anti-CD3 (145-2C11) (1.33 g/mouse) 4 weeks after cell transfer and within
2 days of control recipient mice becoming diabetic. Splenocytes were isolated
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FIG. 1. ATRA treatment inhibits type 1 diabetes. A: Phenotype, cytokine secretion proﬁle, and Foxp3 expression of T-cells present in donor
splenocytes used for adoptive transfer. Representative example of splenocytes isolated from more than ﬁve new-onset diabetic NOD mice were
surface-stained with anti-CD4, -CD8, or -TCR -chain and intracellular-stained using anti–IFN-, –granzyme B, –IL-4, –IL-17, or -Foxp3. B:
Cumulative incidence of diabetes in recipient mice adoptively transferred with splenocytes from new-onset diabetic NOD mice with ATRA
treatment was signiﬁcantly different (P  0.0001) from those without treatment (eight mice per group). Splenocytes were intravenously
transferred into NOD/scid mice, treated with ATRA or vehicle on the day of cell transfer. C: Varied degrees of insulitis detected in recipient mice
at different time points after cell transfer. H/E staining of pancreatic sections isolated from control or ATRA-treated recipient mice after cell
transfer (n  4 mice/group). There are no control mice available for staining on week 17 after cell transfer, since all control mice developed
diabetes by week 4. D: Cumulative incidence of spontaneous diabetes in NOD mice with or without ATRA treatment. NOD mice (10 weeks old)
were treated with ATRA or vehicle every other day from day 1 of cell transfer until 30 weeks old. ATRA treatment signiﬁcantly inhibited
spontaneous disease progress in NOD mice (26 mice/group; P  0.0005). (Please see http://dx.doi.org/10.2337/db08-1154 for a high-quality digital
representation of this ﬁgure.)
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6 cells/ml, 2 or 4 h) in 96-well plates
with RPMI medium plus 5% FBS. The cell culture supernatant was harvested
for IFN- enzyme-linked immunosorbent assay (ELISA).
CD4
 cell in vitro differentiation assay. CD4
 T-cells (10
6 cells/ml) from
newly diabetic mice were activated in 96-well plates with anti-CD3 and
anti-CD28 (5 g/ml) with or without ATRA (1 mol/l). Th1-conditioned
cultures were supplemented with IL-12 (10 ng/ml) and anti–IL-4 (10 g/ml)
(19). Th17-conditioned cultures contained IL-6 (10 ng/ml), TGF-1 (5 ng/ml),
anti–IL-4 (10 g/ml), and anti–IFN- (10 g/ml) (19). Cells were cultured for 3
days and then stained with antibodies against IFN- and IL-17.
Detection of T-bet and Stat-4 expression in T-cells. Four weeks after
splenocyte transfer, splenic T-cells from diabetic control and nondiabetic
ATRA-treated mice were stimulated (3 h) using phorbol myristate acetate and
ionomycin, lysed with 1% Triton X-100; cell lysates were used for Western blot
analyses.
Statistical analysis. Kaplan-Meier survival analysis was used to compare
cumulative diabetes incidence. The Student’s t test was used for data analyses
of all other studies. Signiﬁcance was set at P  0.05.
RESULTS
ATRA treatment inhibits type 1 diabetes. We used an
adoptive transfer animal model of the disease to elucidate
the mechanisms underlying the potential immunoregula-
tory effect of ATRA on type 1 diabetes. Splenocytes
isolated from newly diabetic NOD mice were adoptively
transferred to NOD/scid recipient mice. Donor T-cell phe-
notype, including CD4
 versus CD8
 T-cells, percentage
of CD4
 Foxp3-expressing Treg cells, CD8
 cells express-
ing different markers, and their cytokine secretion proﬁle
are shown in Fig. 1A. The data showed that control
recipient mice developed diabetes within 3 weeks, and all
mice became diabetic within 4 weeks of cell transfer (Fig.
1B). In comparison, ATRA treatment (every other day, as
of day 1 of cell transfer) not only signiﬁcantly delayed the
onset of diabetes for 5 weeks in recipient mice but also
signiﬁcantly reduced diabetes incidence compared with
controls (25% vs. 100%, respectively) (Fig. 1B). Histolog-
ical studies of pancreases from recipient mice showed
that control mice had already developed severe destruc-
tive insulitis 2 weeks after cell transfer, whereas either
intact islets or stationary peri-insulitis was observed in
ATRA-treated mice as late as week 17 after cell transfer
(Fig. 1C).
The effects of ATRA treatment on spontaneous diabetes
development in NOD mice was also analyzed in studies
where treatment was only initiated at 10 weeks of age. At
this age, 2 weeks before the onset of overt diabetes, it is
known that destructive insulitis has developed for several
weeks (25–27). Our data showed that ATRA treatment of
pre-diabetic NOD mice with established insulitis signiﬁ-
cantly reduced diabetes incidence to 30% compared with
70% in control untreated NOD mice (Fig. 1D), demonstrat-
ing that ATRA treatment was able to inhibit diabetes
progress, although severe insulitis had already occurred in
these animals.
ATRA treatment decreases the number of islet-inﬁl-
trating CD8
 cells and suppresses their activation
and IFN-/granzyme B production. Several possibilities
exist that may explain the inhibition of diabetes develop-
ment by ATRA, including 1) reduction of Teff cell number,
2) suppression of activation and/or function of Teff cells,
and 3) expansion of Treg cell number and/or enhancement
of their function. To address these possibilities, we ﬁrst
determined whether ATRA treatment affected the number
of CD4
 and CD8
 T-cells present in recipient mice
transferred with splenocytes isolated from newly diabetic
NOD mice. Our results showed that compared with con-
trols, the percentage and number of islet-inﬁltrating CD8

T-cells, but not CD4
 T-cells, was signiﬁcantly reduced in
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FIG. 2. ATRA treatment decreases the percentage and number of islet-inﬁltrating CD8
 T-cells in recipient mice. A: FACS staining of
islet-inﬁltrating cells (left); number of islet-inﬁltrating CD4
 or CD8
 T-cells isolated from recipient mice (right) at 4 weeks after cell transfer.
B: Number of CD4
 and CD8
 T-cells in spleens (SPL), inguinal lymph nodes (ILN), and pancreatic lymph nodes (PLN). NOD/scid mice adoptively
transferred with splenocytes isolated from newly diabetic NOD mice treated with vehicle or ATRA as of the day of cell transfer; cells were isolated
from recipient mice 4 weeks after cell transfer. Control mice developed diabetes, and ATRA-treated recipient mice remained diabetes free.
Numbers of islet-inﬁltrating CD8
 cells from ATRA-treated mice were signiﬁcantly lower compared with controls. No difference was noted
between control and ATRA-treated mice in islet-inﬁltrating CD4
 cells and CD4
 and CD8
 T-cells in other tissues (n  3 experiments). (Please
see http://dx.doi.org/10.2337/db08-1154 for a high-quality digital representation of this ﬁgure.)
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148 DIABETES, VOL. 58, JANUARY 2009ATRA-treated nondiabetic mice 4 weeks after cell transfer
(Fig. 2A). At this time, all control mice had developed
diabetes. ATRA treatment did not affect the number of
CD4
 or CD8
 T-cells present in spleen and lymph nodes
(Fig. 2B).
To better understand the effect of ATRA treatment on
CD8
 T-cells, we analyzed the phenotype of CD8
 T-cells
and their activation status in recipient mice 4 weeks after
cell transfer, by quantifying the expression of CD45RB,
CD44, CD62L, and CD69. Fluorescence-activated cell
sorter (FACS) data revealed that the percentage of CD8

T-cells expressing a higher level of CD45RB in pancreatic
lymph nodes and islets was signiﬁcantly greater in ATRA-
treated mice than in control recipient mice (Fig. 3A). No
differences were noted in CD44, CD62L, and CD69 expres-
sion (data not shown). Similarly, ATRA treatment did not
alter the percentage of CD45RB-expressing CD8
 T-cells
present in inguinal lymph nodes or spleens. These results
showed that ATRA treatment blocked the downregulation
of CD45RB on CD8
 T-cells and helped retain the expres-
sion of a higher level of CD45RB on CD8
 T-cells in
pancreatic lymph nodes and, in particular, islets. It is
known that CD45RB is downregulated upon activation of
T-cells through their TCRs, indicating T-cell activation
status (28). Therefore, compared with CD8
 T-cells
present in pancreatic lymph nodes and islets of control
mice, expression of a higher level of CD45RB on CD8

T-cells in these two tissues suggested that these CD8

T-cells were kept in a relatively less activated or inacti-
vated status after ATRA treatment.
To further evaluate the effect of ATRA treatment on the
functional status of CD8
 T-cells in recipient mice, we
examined the expression of granzyme B and IFN- expres-
sion in CD8
 T-cells. Previous studies showed that expres-
sion of granzyme B or IFN- by CD8
 T-cells either
directly or indirectly contributed to CD8
 cell–mediated
-cell death (3,5,29). Our results indicated that in ATRA-
treated recipient mice, the percentage of CD8
 T-cells
expressing IFN- alone or both granzyme B and IFN- was
reduced not only in pancreatic lymph nodes and islets but
also in spleen and inguinal lymph nodes, compared with
controls (Fig. 3B).
Our results suggested that ATRA treatment negatively
regulated the activation and function of CD8
 Teff cells, in
particular those inﬁltrating the islets, and maintained them in
a relatively inactive status upon exposure to -cell antigens.
ATRA treatment suppresses IFN-– but not IL-17–
producing CD4
 T-cells in vivo. Although the number of
islet-inﬁltrating CD4
 cells was not altered (Fig. 2A),
ATRA treatment could potentially affect the functional
status of CD4
 Teff cells and the differentiation of Th1 or
Th17 cell lineages in recipient mice. While previous re-
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FIG. 3. Effects of ATRA treatment on the functional and activation status of CD8
 T-cells. A: FACS analyses of CD45RB expression. ATRA
treatment blocked CD45RB downregulation on CD8
 T-cells in pancreatic lymph nodes (PLN) and islets (ISL) compared with control recipient
mice (left). Percentage of CD45RB
 cells in CD8
 T-cells in pancreatic lymph nodes and islets with or without ATRA treatment (right). A,
ATRA-treated; C, control; ILN, inguinal lymph nodes; SPL, spleen. B: Intracellular FACS analyses of granzyme B and IFN- expression in CD8

T-cells (left). ATRA treatment resulted in decreased granzyme B and IFN- expression in CD8
 T-cells in ISL, PLN, SPL, and ILN of NOD/scid
recipient mice. Average percentage of CD8
 cells that expressed IFN- or IFN- and granzyme B in PLN and ISL with or without ATRA treatment
(right)( n  2) is shown. Control mice developed diabetes, whereas ATRA-treated recipient mice remained diabetes-free at 4 weeks after cell
transfer.
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DIABETES, VOL. 58, JANUARY 2009 149search in vitro has demonstrated ATRA regulation of Th1
and Th17 cell differentiation from naive CD4
 T-cells
isolated from normal mice (18–20), its effects on the in vitro
differentiation of CD4
 T-cells isolated from diabetic NOD
mice are not known. We addressed this question by main-
taining CD4
 splenic T-cells, puriﬁed from diabetic NOD
mice, under culture conditions biased toward either Th1 or
Th17 cell differentiation. The results from intracellular cyto-
kine staining showed that, when compared with controls,
addition of ATRA to cell cultures signiﬁcantly reduced the
percentage of IFN-– and IL-17–producing cells cultured
under Th1 and Th17 conditions, respectively (Fig. 4).
We next investigated whether ATRA treatment had
similar negative effects on Th1 and Th17 cells in vivo; in
particular, we examined the percentage of IFN-– and
IL-17–producing cells in recipient mice. Cells isolated from
pancreatic lymph nodes and islets of recipient mice were
analyzed by intracellular cytokine staining 4 weeks after
cell transfer. The results showed that the percentage of
IFN-–producing CD4
 cells was signiﬁcantly reduced in
both pancreatic lymph nodes and islets of ATRA-treated
recipient mice compared with controls (Fig. 5A and B).
However, unexpectedly, the percentage of IL-17–produc-
ing CD4
 cells was not signiﬁcantly changed in these
tissues, nor was there an effect on IL-4–producing CD4

cells (Fig. 5A).
Given that ATRA treatment had negative in vivo effects
on both CD4
 and CD8
 IFN-–producing T-cells, we
further evaluated the in vivo effects on IFN- production in
response to anti-CD3 stimulation in ATRA-treated recipi-
ent mice. Control and ATRA-treated recipient mice were
injected intravenously with an anti-CD3 antibody, and
splenocytes were isolated after antibody injection and
cultured (2 and 4 h) in nonconditioned medium. ELISA
results demonstrated a signiﬁcant reduction in IFN-
production by splenocytes from ATRA-treated animals, at
both time points, compared with controls (Fig. 5C).
Biochemical studies were used to further conﬁrm the
effects of ATRA treatment on IFN-–producing T-cells.
Western blot data showed that expression of STAT4 and
T-bet transcription factors, which are critical to IFN-
production and Th1 cell differentiation (30–32), were
signiﬁcantly reduced (48.9% in STAT4 and 83.3% in T-bet
expression) in T-cells from ATRA-treated mice compared
with untreated controls (Fig. 5D).
ATRA treatment leads to the expansion of Foxp3

Treg cells in vivo. We next examined whether ATRA
treatment also resulted in the expansion of Foxp3
 CD4

Treg cells in vivo. Cells from various tissues of control and
ATRA-treated recipient mice were isolated 4 weeks after
cell transfer. Isolated cells were ﬁrst surface stained with
ani-CD4 and anti-TCR  antibody and then intracellularly
stained with anti-Foxp3 antibody. FACS analysis data
showed that the percentage of Foxp3
 CD4
 Treg cells
present in the spleen, inguinal lymph nodes, pancreatic
lymph nodes, and islets was signiﬁcantly increased in
ATRA-treated recipient mice compared with controls (Fig.
6A and B). Our in vivo study results demonstrated that
ATRA treatment not only suppressed IFN-–producing
Teff cells but also promoted the expansion of Foxp3

CD4
 Treg cells without affecting Th17 cells.
Depletion of CD4
CD25
 T-cells impairs the protec-
tive effect of ATRA treatment on diabetes. We further
examined whether the inhibitory effects of ATRA treatment
on diabetes were dependent upon Foxp3
 CD4
 Treg cells.
CD4
CD25
 cells were depleted from donor splenocytes
isolated from newly diabetic NOD mice, and CD4
CD25

splenocytes (Fig. 7A) were transferred into NOD/scid recip-
ient mice. Our results demonstrated that control and ATRA-
treated recipient mice developed accelerated diabetes and
the kinetics of disease progression was nearly identical in
both (Fig. 7B). Therefore, depletion of CD4
CD25
 T-cells
from donor cells impaired the protective effect of ATRA
treatment on diabetes development.
Further analysis of islet-inﬁltrating lymphocytes isolated
from recipient mice transferred with CD4
CD25
-de-
pleted splenocytes showed that, unlike that observed in
recipient mice transferred with nondepleted splenocytes
(Fig. 2A), there were no differences in the percentage and
number of CD8
 T-cells in control versus ATRA-treated
mice (Fig. 7C). In addition, unlike the differences previ-
ously observed in CD45RB (Fig. 3A), no differences were
noted in CD45RB expression on CD8
 T-cells in pancre-
atic lymph nodes and islets isolated from control and
ATRA-treated recipient mice transferred with CD4

CD25
-depleted splenocytes (Fig. 8A). The results sug-
gested that in the absence of a sufﬁcient number of Treg,
ATRA treatment failed to maintain islet-inﬁltrating CD8

T-cells at a relatively less activated state.
The results also showed that the percentage of CD8

T-cells expressing either IFN- alone or IFN- and gran-
zyme B was reduced in pancreatic lymph nodes and islets
of ATRA-treated recipient mice transferred with CD4

CD25
-depleted splenocytes (Fig. 8B). However, despite
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FIG. 4. ATRA suppresses in vitro differentiation of CD4
 T-cells from
diabetic NOD mice into either IFN-– or IL-17–producing cells. A:
Intracellular FACS staining of CD4
 T-cells cultured under conditions
favoring either Th1 or Th17 cell differentiation. Addition of ATRA to
CD4
 T-cells cultured under conditions toward either Th1 or Th17 cell
differentiation suppressed IFN-– and IL-17–producing cells, respec-
tively. B: Effects of ATRA treatment, in vitro, on the percentage of
IFN-– or IL-17–producing cells cultured under either Th1- or Th17-
conditioned medium. Th1-C/Th17-C: control CD4
 cells cultured in the
absence of ATRA with either Th1- or Th17-conditioned medium; Th1-
A/Th17-A: CD4
 cells cultured in the presence of ATRA with Th1- or
Th17-conditioned medium (n  3). (Please see http://dx.doi.org/
10.2337/db08-1154 for a high-quality digital representation of this
ﬁgure.)
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
T-cells expressing either IFN- alone or IFN- and gran-
zyme B in ATRA-treated mice transferred with depleted
splenocytes was still higher than that found in ATRA-
treated recipient mice transferred with nondepleted
splenocytes (Fig. 8B; Fig. 3B). Similarly, while ATRA
treatment also reduced the percentage of IFN--express-
ing CD4
 T-cells in both pancreatic lymph nodes and islets
of mice transferred with CD4
CD25
-depleted spleno-
cytes, their percentage was still higher than that detected
in mice receiving nondepleted splenocytes (Fig. 8C and
Fig. 5A and B). In comparison, ATRA treatment did not
affect IL-17 expression in CD4
 T-cells in pancreatic
lymph nodes or islets from mice transferred with
CD4
CD25
 cell-depleted splenocytes (Fig. 8C). Taken
together, these results demonstrated that in the absence of
a sufﬁcient number of Foxp3
 CD4
 Treg cells, ATRA
treatment could not efﬁciently suppress the activation and
function of both CD8
 and CD4
 Teff cells and conse-
quently failed to inhibit diabetes.
DISCUSSION
The ﬁndings in this report demonstrated that ATRA, a drug
currently used to treat leukemia, effectively induced im-
mune tolerance that inhibited islet inﬂammation and pro-
gression to overt diabetes. These novel ﬁndings extend the
in vivo effects of ATRA on immune tolerance induction
beyond its in vitro effects on CD4
 T-cells. Our results also
implicated CD4
 and CD8
 Teff cells in ATRA-induced
immune tolerance in vivo. ATRA treatment inhibited both
CD4
 and CD8
 IFN-–producing cells without a detect-
able effect on CD4
 IL-17–producing cells. In addition,
ATRA treatment not only suppressed the number but also
the activation and functional status of CD8
 T-cells.
Histological studies further showed that ATRA-treated
nondiabetic animals were free of destructive insulitis,
suggesting that the effects of ATRA on T-cells might have
also prevented their trafﬁcking to and inﬁltration into
islets, thus inhibiting diabetes. In addition to its effect on
Teff cells, our results showed that ATRA treatment pro-
moted the in vivo expansion of Foxp3
 CD4
 Treg cells.
Furthermore, the protective effects were impaired in the
absence of a sufﬁcient number of donor Foxp3
 CD4

Treg cells. Altogether, these ﬁndings support a model in
which ATRA exerted its in vivo disease-protective effect,
at least in part, by suppressing both CD4
 and CD8

IFN-–producing Teff cells but not IL-17–producing Teff
cells, while promoting the expansion of Treg cells. In
addition, this suppressive effect on Teff cells was depen-
dent on the presence of Foxp3
 CD4
 Treg cells.
Our data provide novel insights as to how ATRA treat-
ment induces immune tolerance, by suppressing both
CD4
 and CD8
 Teff cells. IFN-–producing CD4
 Th1
cells and CD8
 Tc1 cells have been implicated in the
pathogenesis of autoimmune diseases (3–5). Previous
studies have demonstrated that both CD4
 and CD8
 Teff
cells were involved in the onset and further development
of type 1 diabetes (33–35). Our results suggested ATRA
treatment signiﬁcantly downregulated both the percentage
of IFN-–producing CD4
 and CD8
 T-cells and the
amount of IFN- produced by T-cells under in vitro and in
vivo conditions. An unexpected ﬁnding of our study was
that ATRA treatment did not alter the Th17 cell popula-
tion, despite the fact that ATRA inhibited the in vitro
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DIABETES, VOL. 58, JANUARY 2009 151differentiation of Th17 cells (Fig. 4) (18–20,23). Although
Th17 cells may play an important role in pathogenesis in
inﬂammatory bowel disease, experimental autoimmune
encephalitis, and autoimmune arthritis (36–38), the role of
Th17 cells in type 1 diabetes is not clear. Our data
demonstrated that ATRA inhibited diabetes by suppress-
ing both Th1 and Tc1 cells, without affecting Th17 cells.
These results suggested that under these conditions, a pre-
sumably normal Th17 cell population alone was not able to
induce type 1 diabetes and further demonstrated that one of
the mechanisms by which ATRA effectively induced immune
tolerance and inhibited diabetes was through the suppres-
sion of CD4
 Th1 and CD8
 Tc1 cells.
Our results further showed that ATRA treatment was
able to suppress both the activation and functional status
of islet-inﬁltrating CD8
 Teff cells in recipient mice. In
control recipient mice, islet-inﬁltrating CD8
 T-cells
downregulated the expression of CD45RB compared with
that observed in other peripheral lymphoid tissues, includ-
ing inguinal lymph nodes and the spleen. Downregulation
of CD45RB in these islet-inﬁltrating CD8
 T-cells indicated
they had been activated in the islets, which might have
occurred after the encounter of their TCRs with their islet
autoantigens. In comparison, CD45RB expression was not
downregulated on islet-inﬁltrating CD8
 T-cells in ATRA-
treated recipient mice, suggesting that ATRA suppressed
the activation of these T-cells. Moreover, expression of
granzyme B plays an important role in CD8
 Teff cell
function (39). ATRA treatment suppressed granzyme B
expression, especially coexpression with IFN-, in islet-
inﬁltrating CD8
 T-cells, effectively suppressing the func-
tional activation of islet-inﬁltrating CD8
 T-cells in an
environment where they could easily encounter and be
activated by their islet autoantigens. ATRA treatment also
effectively prevented inﬁltration of T-cells into islets, thus
precluding the development of destructive insulitis and
diabetes. Histological analyses data showed that, although
control recipient mice had already developed severe de-
structive insulitis at 2 weeks after cell transfer, only intact
islets or peri-insulitis was detected in ATRA-treated recip-
ient mice, even at a later time point (17 weeks after cell
transfer). Therefore, by preventing recruitment of patho-
genic T-cells to the islets, ATRA treatment might also
prevent diabetes.
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treatment on various T-cell subsets and its subsequent
protection against diabetes remain to be formally ad-
dressed. For example, it is currently unknown whether the
increase in Treg cells occurred concomitantly with a
decrease in Teff cells or whether these were separate or
sequential events. One possibility is that ATRA induces an
early expansion of Treg cells, which results in the suppres-
sion of both CD4
 and CD8
 Teff cells. However, our
results that only islet-inﬁltrating CD8
 cell numbers were
reduced by ATRA treatment suggest that a mechanism
other than a simple expansion of Treg cells is responsible
for the loss of CD8
 T-cells. Another possibility is that
Treg cell expansion after ATRA treatment might affect a
third cell population, which would lead to the selective
suppression of different Teff cell subsets. Previous studies
have suggested that Treg cells do not interact directly with
Teff cells; instead, they may suppress target Teff cells
through the interaction with antigen-presenting cells
(40,41). Our results do not exclude the possible involve-
ment of, for example, dendritic natural killer T-cells and
natural killer cells, which have been suggested to play a
role during islet inﬂammation and diabetes onset (27,42–
46). Further studies are needed to determine the relative
contribution of these different possibilities.
A novel ﬁnding in our study was that the disease-
protection effect of ATRA was blocked when CD4
CD25

T-cells, thus a majority of Foxp3
 Treg, were depleted
from donor splenocytes. While the mechanisms responsi-
ble for the Treg dependency in ATRA’s disease protection
effects remain largely unclear, we found that ATRA treat-
ment did not reduce the number of islet-inﬁltrating CD8

T-cells in recipient mice transferred with CD4
CD25

splenocytes. Although the percentage of CD4
 or CD8

T-cells producing IFN- alone or CD8
 cells producing
both IFN- and granzyme B were reduced in recipient
mice, the reduction level was less than that detected in
recipient mice transferred with nondepleted splenocytes.
These results indicated that after depletion of Treg cells from
donor cells, ATRA treatment failed to inhibit diabetes, at
least due in part to its inefﬁciency in suppressing these Teff
cells. Future studies will further elucidate the molecular and
cellular mechanisms underlying this Treg dependency.
In this article, we have focused on ATRA’s effects in vivo
on various populations of T-cells. Based on our ﬁndings,
the dual in vivo effects of ATRA treatment, namely, the
suppression of Teff cells and the promotion of Treg cell
expansion, may distinguish the use of ATRA from other
interventions that affect either Treg or Teff cells, as a
therapeutic method for type 1 diabetes. Although ATRA
treatment was able to inhibit spontaneous type 1 diabetes
in pre-diabetic NOD mice with established insulitis, to
further validate and establish the potential of using ATRA
for therapy, not just prevention, it will be important for
future studies to examine whether, other than using the
adoptive transfer mouse model, ATRA treatment can in-
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nonmanipulated NOD mice. If so, it will also be important
to uncover whether the same cellular and molecular
mechanisms underlie the tolerance-inducing effect of
ATRA in these mice. Furthermore, because ATRA is
FDA-approved for the treatment of leukemia and skin
disease, its well-studied toxicity and metabolic kinetics in
humans suggest a clear advantage for its clinical use over
other methods that might still require extensive human
trials. Overall, our data support the use of ATRA treatment
to induce immune tolerance may provide an effective
method to inhibit type 1 diabetes.
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